Optimizing TACE for Hepatocellular Carcinoma: The Impact of Intra-Arterial Contrast Enhanced Ultrasound
Abstract
:1. Introduction
2. Challenges in Traditional TACE Procedure
3. Evaluation of Treatment’s Response
4. CEUS: Enhancing Imaging Precision in HCC
4.1. Microvascular Imaging and Safety of CEUS
4.2. CEUS Accuracy in Post-TACE Residual Tumor Detection
5. IA-CEUS: Transforming Real-Time Tumor Targeting
6. Conclusions
Author Contributions
Funding
Data Availability Statement
Conflicts of Interest
Abbreviations
ACR | American College of Radiology |
ALDA | Alcohol-related Liver Disease |
APHE | Arterial Phase Hyperenhancement |
AUC | Area Under the Curve |
AUROC | Area Under the Receiver Operating Characteristic Curve |
BCLC | Barcelona Clinic Liver Cancer |
CE-MRI | Contrast-Enhanced Magnetic Resonance Imaging |
c-TACE | Conventional Transarterial Chemoembolization |
CEUS | Contrast-Enhanced Ultrasound |
CIN | Contrast-Induced Nephropathy |
CT | Computed Tomography |
DCE-US | Dynamic Contrast-Enhanced Ultrasound |
DEB-TACE | Drug-Eluting Bead Transarterial Chemoembolization |
DSA | Digital Subtraction Angiography |
DWI | Diffusion-Weighted Imaging |
FPS | Frames Per Second |
HCC | Hepatocellular Carcinoma |
HBV | Hepatitis B Virus |
HCV | Hepatitis C Virus |
IA-CEUS | Intra-Arterial Contrast-Enhanced Ultrasound |
LI-RADS | Liver Imaging Reporting and Data System |
MASLD | Metabolic dysfunction-associated Steatotic Liver Disease |
MHz | Megahertz |
MI | Mechanical Index |
mRECIST | Modified Response Evaluation Criteria in Solid Tumors |
MRI | Magnetic Resonance Imaging |
mTT | Mean Transit Time |
NSF | Nephrogenic Systemic Fibrosis |
PE | Peak Enhancement |
PES | Postembolization Syndrome |
RCT | Randomized Controlled Trial |
RT | Rise Time |
SMA | Superior Mesenteric Artery |
T2WI | T2-Weighted Imaging |
TACE | Transarterial Chemoembolization |
TIC | Time-Intensity Curve |
TRA | Transarterial |
TTP | Time to Peak |
WiR | Wash-in Rate |
3D-CEUS | Three-Dimensional Contrast-Enhanced Ultrasound |
References
- Yang, J.D.; Hainaut, P. A global view of hepatocellular carcinoma: Trends, risk, prevention and management. Nat. Rev. Gastroenterol. Hepatol. 2019, 16, 589–604. [Google Scholar] [CrossRef] [PubMed]
- Russo, F.P.; Zanetto, A. Hepatocellular Carcinoma in Chronic Viral Hepatitis: Where Do We Stand? Int. J. Mol. Sci. 2022, 23, 500. [Google Scholar] [CrossRef]
- Argenziano, M.E.; Kim, M.N. Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients. Hepatol. Int. 2024, 18 (Suppl. S2), 922–940. [Google Scholar] [CrossRef] [PubMed]
- Wang, W.; Wei, C. Advances in the early diagnosis of hepatocellular carcinoma. Genes. Dis. 2020, 7, 308–319. [Google Scholar] [CrossRef]
- Majno, P.; Mentha, G. Anatomy of the liver: An outline with three levels of complexity–A further step towards tailored territorial liver resections. J. Hepatol. 2014, 60, 654–662. [Google Scholar] [CrossRef]
- Kinsey, E.; Lee, H.M. Management of Hepatocellular Carcinoma in 2024: The Multidisciplinary Paradigm in an Evolving Treatment Landscape. Cancers 2024, 16, 666. [Google Scholar] [CrossRef] [PubMed]
- Reig, M.; Forner, A. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. J. Hepatol. 2022, 76, 681–693. [Google Scholar] [CrossRef]
- Tabori, N.E.; Sivananthan, G. Treatment Options for Early-Stage Hepatocellular Carcinoma. Semin. Interv. Radiol. 2020, 37, 448–455. [Google Scholar] [CrossRef]
- European Association for the Study of the Liver. EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J. Hepatol. 2025, 82, 315–374. [Google Scholar] [CrossRef]
- Cho, Y.; Choi, J.W. Research Committee of the Korean Liver Cancer Association. Transarterial chemoembolization for hepatocellular carcinoma: 2023 Expert consensus-based practical recommendations of the Korean Liver Cancer Association. Clin. Mol. Hepatol. 2023, 29, 521–541. [Google Scholar] [CrossRef]
- Sutphin, P.D.; Lamus, D. Interventional Radiologic Therapies for Hepatocellular Carcinoma: From Where We Began to Where We Are Going. In Hepatocellular Carcinoma: Translational Precision Medicine Approaches; Hoshida, Y., Ed.; Humana Press: Cham, Switzerland, 2019; Chapter 9. [Google Scholar]
- Ribeiro, C.; Barreira, J. P-047: Effectiveness of TACE as bridge therapy for liver transplant in hepatocellular carcinoma. Ann. Oncol. 2016, 27 (Suppl. S2), ii14. [Google Scholar] [CrossRef]
- Xia, D.; Bai, W. HCC-TACE study group. Tumor burden with AFP improves survival prediction for TACE-treated patients with HCC: An international observational study. JHEP Rep. 2024, 7, 101216. [Google Scholar] [CrossRef]
- Nandy, K.; Varty, G.P. Role of preoperative transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma (Hong Kong liver cancer stage IIB). World J. Surg. 2025, 49, 483–493. [Google Scholar] [CrossRef]
- Facciorusso, A. Drug-eluting beads transarterial chemoembolization for hepatocellular carcinoma: Current state of the art. World J. Gastroenterol. 2018, 24, 161–169. [Google Scholar] [CrossRef] [PubMed]
- Yang, Y.; Dang, Z. Impact of pathological response after preoperative transcatheter arterial chemoembolization (TACE) on incidences of microvascular invasion and early tumor recurrence in hepatocellular carcinoma: A multicenter propensity score matching analysis. Hepatobiliary Surg. Nutr. 2022, 11, 386–399. [Google Scholar] [CrossRef] [PubMed]
- Douhara, A.; Namisaki, T. Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization. Oncol. Lett. 2017, 14, 3028–3034. [Google Scholar] [CrossRef] [PubMed]
- McGillen, K.L.; Pryor, W.W., 3rd. Accuracy of Contrast-Enhanced Ultrasound for Hepatocellular Carcinoma Post-Transcatheter Arterial Embolization. J. Clin. Med. 2024, 13, 7720. [Google Scholar] [CrossRef]
- Faccia, M.; Garcovich, M. Contrast-Enhanced Ultrasound for Monitoring Treatment Response in Different Stages of Hepatocellular Carcinoma. Cancers 2022, 14, 481. [Google Scholar] [CrossRef]
- Llovet, J.M.; Real, M.I. Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002, 359, 1734–1739. [Google Scholar] [CrossRef]
- Lo, C.M.; Ngan, H. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002, 35, 1164–1171. [Google Scholar] [CrossRef]
- Llovet, J.M.; Brú, C. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin. Liver Dis. 1999, 19, 329–338. [Google Scholar] [CrossRef] [PubMed]
- Lencioni, R.; de Baere, T. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology 2016, 64, 106–116. [Google Scholar] [CrossRef] [PubMed]
- Lee, H.N.; Hyun, D. Complications Related to Transarterial Treatment of Hepatocellular Carcinoma: A Comprehensive Review. Korean J. Radiol. 2023, 24, 204–223. [Google Scholar] [CrossRef]
- Chen, M.J.; Lin, C.C. Biloma following repeated transcatheter arterial embolization and complicated by intrahepatic duct stones: A case report. World J. Gastroenterol. 2005, 11, 4764–4765. [Google Scholar] [CrossRef]
- Lammer, J.; Malagari, K. PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study. Cardiovasc. Interv. Radiol. 2010, 33, 41–52. [Google Scholar] [CrossRef]
- Makary, M.S.; Alexander, J. Clinical outcomes of DEB-TACE in locally advanced hepatocellular carcinoma: A 5-year real world experience. PLoS ONE 2024, 19, e0309693. [Google Scholar] [CrossRef]
- Albrecht, K.C.; Aschenbach, R. Response rate and safety in patients with hepatocellular carcinoma treated with transarterial chemoembolization using 40-µm doxorubicin-eluting microspheres. J. Cancer Res. Clin. Oncol. 2021, 147, 23–32. [Google Scholar] [CrossRef]
- Facciorusso, A.; Di Maso, M. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma: A meta-analysis. Dig. Liver Dis. 2016, 48, 571–577. [Google Scholar] [CrossRef] [PubMed]
- Therasse, P.; Arbuck, S.G. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J. Natl. Cancer Inst. 2000, 92, 205–216. [Google Scholar] [CrossRef]
- Kim, B.K.; Kim, S.U. Complete response at first chemoembolization is still the most robust predictor for favorable outcome in hepatocellular carcinoma. J. Hepatol. 2015, 62, 1304–1310. [Google Scholar] [CrossRef]
- Lencioni, R.; Llovet, J.M. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin. Liver Dis. 2010, 30, 52–60. [Google Scholar] [CrossRef] [PubMed]
- Brennan, I.M.; Ahmed, M. Imaging features following transarterial chemoembolization and radiofrequency ablation of hepatocellular carcinoma. Semin. Ultrasound CT MRI 2013, 34, 336–351. [Google Scholar] [CrossRef] [PubMed]
- Park, W.; Chung, Y.H. Recurrences of hepatocellular carcinoma following complete remission by transarterial chemoembolization or radiofrequency therapy: Focused on the recurrence patterns. Hepatol. Res. 2013, 43, 1304–1312. [Google Scholar] [CrossRef] [PubMed]
- Kloeckner, R.; Otto, G. MDCT versus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc. Interv. Radiol. 2010, 33, 532–540. [Google Scholar] [CrossRef]
- Kamel, I.R.; Liapi, E. Unresectable hepatocellular carcinoma: Serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 2009, 250, 466–473. [Google Scholar] [CrossRef]
- Yaghmai, V.; Besa, C. Imaging assessment of hepatocellular carcinoma response to locoregional and systemic therapy. Am. J. Roentgenol. 2013, 201, 80–96. [Google Scholar] [CrossRef]
- Chung, W.S.; Lee, K.H. Enhancement patterns of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads on arterial phase CT images: A pilot retrospective study. Am. J. Roentgenol. 2012, 199, 349–359. [Google Scholar] [CrossRef]
- Sheng, R.; Yang, C. The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value. Radiol. Med. 2023, 128, 1047–1060. [Google Scholar] [CrossRef]
- Dietrich, C.F.; Nolsøe, C.P. Guidelines and Good Clinical Practice Recommendations for Contrast-Enhanced Ultrasound (CEUS) in the Liver-Update 2020 WFUMB in Cooperation with EFSUMB, AFSUMB, AIUM, and FLAUS. Ultrasound Med. Biol. 2020, 46, 2579–2604. [Google Scholar] [CrossRef]
- McGillen, K.L.; Zaidi, S. Contrast-Enhanced Ultrasonography for Screening and Diagnosis of Hepatocellular Carcinoma: A Case Series and Review of the Literature. Medicines 2020, 7, 51. [Google Scholar] [CrossRef]
- Sridharan, A.; Eisenbrey, J.R. Ultrasound contrast agents: Microbubbles made simple for the pediatric radiologist. Pediatr. Radiol. 2021, 51, 2117–2127. [Google Scholar] [CrossRef] [PubMed]
- Lai, T.Y.; Averkiou, M.A. Contrast-Enhanced Ultrasound with Optimized Aperture Patterns and Bubble Segmentation Based on Echo Phase. Ultrasound Med. Biol. 2023, 49, 186–202. [Google Scholar] [CrossRef] [PubMed]
- Averkiou, M.A.; Bruce, M.F. Imaging Methods for Ultrasound Contrast Agents. Ultrasound Med. Biol. 2020, 46, 498–517. [Google Scholar] [CrossRef] [PubMed]
- Al-Jawadi, S.; Thakur, S.S. Ultrasound-responsive lipid microbubbles for drug delivery: A review of preparation techniques to optimise formulation size, stability and drug loading. Int. J. Pharm. 2020, 585, 119559. [Google Scholar] [CrossRef] [PubMed]
- Shaw, C.M.; Eisenbrey, J.R. Contrast-enhanced ultrasound evaluation of residual blood flow to hepatocellular carcinoma after treatment with transarterial chemoembolization using drug-eluting beads: A prospective study. J. Ultrasound Med. 2015, 34, 859–867. [Google Scholar] [CrossRef]
- Sugimoto, K.; Moriyasu, F. Assessment of arterial hypervascularity of hepatocellular carcinoma: Comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging. Eur. Radiol. 2012, 22, 1205–1213. [Google Scholar] [CrossRef]
- Escalante, C.M.K.Y.; Xiao, T.S.; Nagaraj, R.U.; Savsani, E.; Mohammed, A.; Li, J.; Lyshchik, A.; Liu, J.-B.; Wessner, C.E.; Tahmasebi, A.; et al. Evaluation of the Contrast-Enhanced Ultrasound Nonradiation Treatment Response Assessment LI-RADS v2024 Using Data From a Multi-Center Transarterial Chemoembolization Study. Acad. Radiol. 2024, 31, 5078–5086. [Google Scholar] [CrossRef]
- Xia, Y.; Kudo, M. Response evaluation of transcatheter arterial chemoembolization in hepatocellular carcinomas: The usefulness of sonazoid-enhanced harmonic sonography. Oncology 2008, 75 (Suppl. S1), 99–105. [Google Scholar] [CrossRef]
- Takizawa, K.; Numata, K. Use of contrast-enhanced ultrasonography with a perflubutane-based contrast agent performed one day after transarterial chemoembolization for the early assessment of residual viable hepatocellular carcinoma. Eur. J. Radiol. 2013, 82, 1471–1480. [Google Scholar] [CrossRef]
- Paul, S.B.; Dhamija, E. Evaluation of tumor response to intra-arterial chemoembolization of hepatocellular carcinoma: Comparison of contrast-enhanced ultrasound with multiphase computed tomography. Diagn. Interv. Imaging 2017, 98, 253–260. [Google Scholar] [CrossRef]
- Zhong, J.; Su, Z. Contrast-Enhanced Ultrasonography Versus Contrast-Enhanced Computed Tomography for Assessment of Residual Tumor From Hepatocellular Carcinoma Treated with Transarterial Chemoembolization: A Meta-analysis. J. Ultrasound Med. 2018, 37, 1881–1890. [Google Scholar] [CrossRef]
- Lee, C.C.; Hwang, J.I. Comparison of contrast-enhanced ultrasonography and MRI results obtained by expert and novice radiologists indicating short-term response after transarterial chemoembolization for hepatocellular carcinoma. Clin. Radiol. 2024, 79, e73–e79. [Google Scholar] [CrossRef]
- Youk, J.H.; Lee, J.M. Therapeutic response evaluation of malignant hepatic masses treated by interventional procedures with contrast-enhanced agent detection imaging. J. Ultrasound Med. 2003, 22, 911–920. [Google Scholar] [CrossRef]
- Moschouris, H.; Malagari, K. Short-term evaluation of liver tumors after transarterial chemoembolization: Limitations and feasibility of contrast-enhanced ultrasonography. Abdom. Imaging 2011, 36, 718–728. [Google Scholar] [CrossRef]
- Dietrich, C.F.; Dong, Y. Dynamic contrast-enhanced endoscopic ultrasound: A quantification method. Endosc. Ultrasound 2017, 6, 12–20. [Google Scholar] [CrossRef]
- Uller, W.; Wiggermann, P. Evaluation of the microcirculation of hepatocellular carcinomas using contrast-enhanced ultrasound with intraarterial and intravenous contrast application during transarterial chemoembolization with drug-eluting beads (DEB-TACE): Preliminary data. Clin. Hemorheol. Microcirc. 2011, 49, 55–66. [Google Scholar] [CrossRef]
- Cao, J.; Dong, Y. Early evaluation of treatment response to transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The role of dynamic three-dimensional contrast-enhanced ultrasound. Clin. Hemorheol. Microcirc. 2021, 78, 365–377. [Google Scholar] [CrossRef]
- Nam, K.; Stanczak, M. Evaluation of Hepatocellular Carcinoma Transarterial Chemoembolization using Quantitative Analysis of 2D and 3D Real-time Contrast Enhanced Ultrasound. Biomed. Phys. Eng. Express. 2018, 4, 035039. [Google Scholar] [CrossRef]
- Savsani, E.; Shaw, C.M. Contrast-enhanced US Evaluation of Hepatocellular Carcinoma Response to Chemoembolization: A Prospective Multicenter Trial. Radiology 2023, 309, e230727. [Google Scholar] [CrossRef]
- Kita, R.; Sakamoto, A. Visualization of blood drainage area from hypervascular hepatocellular carcinoma on ultrasonographic images during hepatic arteriogram: Comparison with depiction of drainage area on contrast-enhanced ultrasound. Hepatol. Res. 2012, 42, 999–1007. [Google Scholar] [CrossRef]
- Lekht, I.; Nayyar, M. Intra-arterial contrast-enhanced ultrasound (IA CEUS) for localization of hepatocellular carcinoma (HCC) supply during transarterial chemoembolization (TACE): A case series. Abdom Radiol. 2017, 42, 1400–1407. [Google Scholar] [CrossRef] [PubMed]
- Fei, X.; Wang, Z.J. The value of intra-procedural transcatheter intraarterial contrast-enhanced ultrasonography (IA-CEUS) in predicting the short-term efficacy of conventional transarterial chemoembolization (cTACE). Transl. Cancer Res. 2020, 9, 3600–3609. [Google Scholar] [CrossRef] [PubMed]
- Shiozawa, K.; Watanabe, M. Efficacy of intra-arterial contrast-enhanced ultrasonography during transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. World J. Hepatol. 2018, 10, 95–104. [Google Scholar] [CrossRef] [PubMed]
- Bo, J.; Peng, H. Intraarterial contrast-enhanced ultrasound to predict the short-term tumour response of hepatocellular carcinoma to Transarterial chemoembolization with Lipiodol. BMC Cancer 2021, 21, 1171. [Google Scholar] [CrossRef]
Study | Design | Patients (n) | Treatment | Results |
---|---|---|---|---|
Llovet JM et al. [20] | Single-institution RCT | 112 | c-TACE vs. Best Supportive Care | HR 0.47 (95% CI 0.25–0.91; p = 0.025); 2-year OS: 63% (TACE) vs. 23% (BSC) |
Lo. Chung-Mau et al. [21] | Single-institution RCT | 80 | c-TACE vs. Best Supportive Care | 2-year OS: 31% (TACE) vs. 11% (BSC); RR of death reduction 0.49 (95% CI 0.29–0.81; p = 0.006) |
Lencioni R. et al. [23] | Meta-analysis | 10,108 | c-TACE | Median OS: 19.4 months (95% CI 16.2–22.6); 1-year OS: 70.3%; 3-year OS: 40.4%; 5-year OS: 32.4%; PES: 4.8%; mortality: 0.6% |
Lammer J. et al. [26] | RCT | 201 | c-TACE vs. DEB-TACE | OR: 27% vs. 22%; DCR: 63% vs. 52%; no statistical superiority (p = 0.11) |
Makary MS et al. [27] | Retrospective | 471 | DEB-TACE | OS: 1-year 64%, 3-year 16.3%, 5-year 2.1%; mean PFS: 6.7 months; 12.5% underwent transplantation |
FOCUS | CEUS | CT | MRI |
---|---|---|---|
Advantages | - Cost-effective. - No concerns about breath holding or claustrophobia. - No radiation or nephrotoxicity risk [41]. | - Widely available. - Lower cost. - Preferred in specific conditions [39]. | - Highly sensitive in detecting HCC recurrence [35]. |
Limitations | - Operator-dependent with higher intra- and inter-reader variability [54]. - Visualization challenges (e.g., obesity, cirrhosis, diaphragm location) [55]. | - Radiation exposure [37]. - Lipiodol® artifacts hinder accurate interpretation [37]. | - Limited sensitivity in patients with ascites [35]. |
Sensitivity in Tumor Detection | - High sensitivity (up to 94%) for detecting residual/ recurrent disease, superior to CT [51]. | - Moderate sensitivity (50%) for detecting residual disease post-TACE [51]. | - Moderate sensitivity (68%) for recurrence [49]. |
Follow-Up Protocol | - 1 and 3 months post-TACE for early detection of recurrence [49]. | - Follow-up at 1 and 3 months, then every 3–6 months [31]. | - Follow-up at 1 and 3 months, then every 3–6 months [31]. |
Evaluation Criteria | - mRECIST criteria for evaluating treatment response [47]. | - mRECIST criteria; hypoattenuation and enhancement patterns for assessment [32,33]. | - mRECIST criteria; additional diffusion-weighted imaging (DWI) for atypical features [36]. |
Early Detection of Viable Tumors | - Detects viable tumors 1–2 days post-TACE [50]. | - Less sensitive for early detection [47]. | - Detects recurrence early but less sensitive than CEUS [35]. |
Advanced Techniques | - DCE-US (dynamic contrast-enhanced ultrasound), 3D-CEUS, IA-CEUS [57,61,62]. | - No advanced techniques for TACE follow-up [37]. | - DWI for atypical post-TACE features [36]. |
Post-Treatment Imaging Features | - Viable tumors show nodular or peripheral enhancement [46]. | - Treated areas show hypoattenuation, no enhancement [33]. | - Treated areas appear hypointense on T2WI [33]. |
Study | Design | Patients (n) | Diagnostic Accuracy Post-TACE | Results |
---|---|---|---|---|
Shaw. CM. et al. [46] | Retrospective | 54 | CEUS vs. RM | Area under the ROC curve (AUC) with CEUS (0.94; 95% confidence interval [CI] 0.88–1.00) vs. gadoxetate disodium-enhanced MR (0.84, 95% CI 0.74–0.93, p = 0.0014) |
Xia Y. et al. [49] | Prospective | 43 | CEUS vs. CECT | Detection rate CEUS (58.1%) vs. CECT (39.5%) (p < 0.05) |
Takizawa K et al. [50] | Prospective | 46 | CEUS vs. CECT | Detection rate CEUS (95.7%) vs. CECT (78.7%) (p < 0.05) |
Paul SB. Et al. [51] | Prospective | 50 | CEUS vs. CECT | Sensitivity: CEUS 94% (34/36; 95% CI: 81–99%); TC 50% (18/36; 95% CI: 33–67%) Specificity: CEUS 100%; TC 100% |
Zhong J. et al. [52] | Meta-analysis | 421 | CEUS vs. CECT | Sensitivity: CEUS 0.97 (95% CI: 0.95–0.99); CECT 0.72 (95% CI: 0.67–0.76) NPV: CEUS 0.90 (0.83–0.95) vs. CECT 0.51 (0.44–0.58) |
McGillen KL. et al. [18] | Prospective | 26 | CEUS vs. CECT/MRI | CEUS: LI-RADS treated 48.7%; LI-RADS viable 61.3% CT/MRI: LI-RADS treated 48.5%; LI-RADS viable 51.5%, p = 0.617 |
Uller W. et al. [57] | Prospective | 11 | DCE-US (before and after DEB-TACE) | Evaluation of microcirculation in HCC i.v. and i.a. CEUS: reduction of vascularization after bead application was correlated significantly with i.a. and i.v. contrast application (p = 0.007) and decreased significantly using TIC analysis (p = 0.003) |
Cao J. et al. [58] | Prospective | 53 | 2D CEUS and 3D CEUS | Analyzed microperfusional changes before and after TACE: area under the ROC curves for significant ratios and differences of dynamic 3D-CEUS perfusion parameters were higher than those for the corresponding parameters of 2D-CEUS |
Nam. K. et al. [59] | Prospective | 17 | 2D CEUS and 3D CEUS vs. MRI | Compared dynamic 2D and 3D CEUS at different time points after TACE: correlation coefficients between 2D and 3D residual tumor estimates in 1–2 weeks post-TACE and the estimates from MRI were 0.73 and 0.94, respectively, while those from 2D and 3D CEUS at 1 month post-TACE were 0.66 and 0.91, respectively. |
Savsani E. et al. [60] | Prospective multicenter trial | 132 | 2D CEUS and 3D CEUS vs. CE-MRI and CECT | Sensitivity: 91% for 2D CEUS, 89% for 3D CEUS, CE-MRI 68% and CECT 58% (p < 0.001) |
Fei X. et al. [63] | Prospective single-center trial | 39 | IA-CEUS | Maximum cross-sectional area ratio of intratumor perfusion (p < 0.001), peak value (p < 0.001) and level of corona enhancement (p < 0.001) showed correlation with tumor response on CE-MRI |
Shiozawa K. et al. [64] | Prospective single-center trial | 32 | IA-CEUS | Overall CR rate at 6 months 61.5% (24/39). |
Bo J. et al. [65] | Case–control single-center study | 44 | IA-CEUS | Area under the receiver operating characteristic curve (AUROC) of the predictive model 0.904 (95% CI: 0.804, 0.966; p < 0.001). |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2025 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Galasso, L.; Iaccarino, J.; Esposto, G.; Giansanti, G.; Mignini, I.; Borriello, R.; Vidili, G.; Gasbarrini, A.; Ainora, M.E.; Zocco, M.A. Optimizing TACE for Hepatocellular Carcinoma: The Impact of Intra-Arterial Contrast Enhanced Ultrasound. Diagnostics 2025, 15, 1380. https://doi.org/10.3390/diagnostics15111380
Galasso L, Iaccarino J, Esposto G, Giansanti G, Mignini I, Borriello R, Vidili G, Gasbarrini A, Ainora ME, Zocco MA. Optimizing TACE for Hepatocellular Carcinoma: The Impact of Intra-Arterial Contrast Enhanced Ultrasound. Diagnostics. 2025; 15(11):1380. https://doi.org/10.3390/diagnostics15111380
Chicago/Turabian StyleGalasso, Linda, Jacopo Iaccarino, Giorgio Esposto, Gabriele Giansanti, Irene Mignini, Raffaele Borriello, Gianpaolo Vidili, Antonio Gasbarrini, Maria Elena Ainora, and Maria Assunta Zocco. 2025. "Optimizing TACE for Hepatocellular Carcinoma: The Impact of Intra-Arterial Contrast Enhanced Ultrasound" Diagnostics 15, no. 11: 1380. https://doi.org/10.3390/diagnostics15111380
APA StyleGalasso, L., Iaccarino, J., Esposto, G., Giansanti, G., Mignini, I., Borriello, R., Vidili, G., Gasbarrini, A., Ainora, M. E., & Zocco, M. A. (2025). Optimizing TACE for Hepatocellular Carcinoma: The Impact of Intra-Arterial Contrast Enhanced Ultrasound. Diagnostics, 15(11), 1380. https://doi.org/10.3390/diagnostics15111380